Fischer C-arm pact offsets lower revenue
Fischer Imaging's revenue is down as it prepares an FDA submission for its SenoScan full-field digital mammography system.Revenue decreased 3% to $13.7 for the first quarter of 2000 (end April 2) compared to $14.2 million for the first quarter of
Fischer Imaging's revenue is down as it prepares an FDA submission for its SenoScan full-field digital mammography system.Revenue decreased 3% to $13.7 for the first quarter of 2000 (end April 2) compared to $14.2 million for the first quarter of 1999. These figures do not include the sale of a $6.2 million technology license to GE Medical.
The deal with GE involves a Fischer design for a C-arm attachment for cardiology equipment. The license agreement says GE can manufacture the C-arm itself or outsource it to another company.
Fischer's net income for the first quarter of 2000 was $351,000 compared to a net loss of $2.4 million for the first quarter of 1999. These figures do not include income from the GE technology license sale.
Despite the 3% revenue decrease, Louis Rivelli, Fischer president and chief operating officer, said the company's net income for first quarter 2000 exceeded projections. He added that the quarter's operating expenses of $5.6 million were the lowest in five years.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
